Udnyttelse af farmaceutteknikere til at fremme rækkevidden af moderne antiretroviral terapi (PHARM ART) i lokalsamfundsklinikker (PHARM ART)
Udnyttelse af apoteksteknikere til at fremme rækkevidden af moderne antiretroviral terapi (PHARM ART) i nærklinikker
Long-acting injectable HIV medication is an important new innovation in HIV treatment, but complex delivery logistics have resulted in limited access for people with HIV (PWH). The goal of this study is to use clinic-based pharmacy technicians to improve delivery of long-acting injectable HIV medication at federally qualified health centers in Chicago.
Participants at the community clinics may be invited to take part in study surveys or interviews. Participants at the community clinics will be part of an observational cohort.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The overarching goal of this proposal is to integrate a pharmacy technician-based model for delivering long-acting injectable cabotegravir-rilpivirine (LA-CAB/RPV) into community-based federally qualified health centers (FQHCs) that care for underserved people with HIV (PWH). LA-CAB/RPV, given every 4 or 8 weeks, is a novel HIV treatment option that positively impacts quality of life and has been shown to improve viral suppression in PWH with adherence challenges. However, rollout has been slow due to complex delivery logistics such as navigating insurance coverage and procuring medication from designated specialty pharmacies. Despite strong interest from PWH and providers, this complexity has prevented many FQHCs, which provide HIV care regardless of ability to pay or insurance, from being able to offer LA-CAB/RPV. Preliminary data from academic HIV clinics demonstrate that a LA-CAB/RPV delivery model which places a pharmacy technician in a key role, along with multidisciplinary case conferences (coalition-building), robust relationships with the specialty pharmacies that supply LA-CAB/RPV (network weaving), and tools for quality monitoring, allows programs to effectively initiate and maintain PWH on treatment. In this study, guided by two implementation science frameworks, the Consolidated Framework of Implementation Research (CFIR 2.0) and Proctor's implementation outcomes, the study will adapt and test the pharm-tech based model in five FQHC clinics in Chicago, assessing cost and equity impacts. Aim 1 will consist of formative work to adapt and refine the pharm tech-based model for the FQHC setting via rapid ethnography and implementation mapping. Aim 2 involves a hybrid Type III implementation-effectiveness study. To evaluate the effect of the PHARM ART model, the study will compare the LA-CAB/RPV initiation rate in implementation clinics vs. a group of contemporaneous control clinics using a controlled interrupted time series design over three phases: before the PHARM ART model (pre-implementation phase - 24 months prior to initiation of PHARM ART), during active facilitation by the study team (implementation phase - 21 months), and with cessation of active facilitation (sustainment phase - 21 months). Using electronic medical record data and iterative qualitative and survey research, the study will delineate mechanisms by which the PHARM ART model works in the FQHC setting, assess the quality of implementation, and evaluate clinical effectiveness outcomes. In Aim 3 the study will estimate cost, budgetary impact and cost-effectiveness of PHARM ART and associated strategies. The study will adapt an existing mathematical model to evaluate epidemiologic and economic impact across populations, applying distributional cost-effectiveness analysis (DCEA) to assess health equity impacts, including scenarios with varying levels of baseline viral suppression. The proposed work will provide important information on implementation strategies and cost/equity considerations to guide decisions by clinics and funders to invest in capacity-building.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Moira McNulty
- Telefonnummer: 773-834-5528
- E-mail: Moira.McNulty@bsd.uchicago.edu
Undersøgelse Kontakt Backup
- Navn: Samantha Devlin
- E-mail: sdevlin1@bsd.uchicago.edu
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients with HIV at implementation sites
- English or Spanish speaking
- Age 15 year and older
- Able to provide informed consent
Exclusion Criteria:
- Inability to provide informed consent due to cognitive deficits, active psychosis, or acute intoxication
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
The primary intervention is the integration of a pharmacy technician into the HIV care team. In addition, several other implementation strategies will be used to support programs in effectively initiating and maintaining people living with HIV on long-acting injectable treatment, including multidisciplinary case conferences, robust relationships with the specialty pharmacies that supply LA-CAB/RPV, and tools for quality monitoring. |
The pharmacy technician will be integrated into the HIV care team, taking referrals, documenting contact information for patients, assessing patient-level barriers to receipt of LA CAB/RPV (social determinants) for discussion with the care team, ensuring drug coverage, coordinating medication delivery and storage, tracking injections, scheduling injections, and completing clinical documentation. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
LA-CAB/RPV Initiation Rate
Tidsramme: Baseline through 42 months
|
Number of LA-CAB/RPV initiations per number of HIV provider visits per month |
Baseline through 42 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Moira McNulty, University of Chicago
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB25-0456
- 1R01MH140440 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .